Bigtincan (ASX:BTH) has raised capital to fund the acquisition of Brainshark Inc.
August 2021 — Bigtincan Holdings Limited (ASX:BTH) has raised US$98.6 via a placement and underwritten accelerated non-renounceable entitlement offer.
Bigtincan is a software company that has developed an AI-powered sales enablement automation platform aimed at achieving improved success of sales and customer satisfaction. The mobile platform solution features the industry’s premier user experience that empowers sales representatives to engage more effectively with customers and prospects, and encourages team-wide adoption.
Our role in the transaction
Oaklins’ team in Australia acted as corporate advisor, joint lead manager and underwriter in this transaction.
David Keane
CEO, Bigtincan Holdings
Talk to the deal team
Related deals
360 Experience Group has merged with GoodFellows
360 Experience Group, a European end-to-end service provider of live experiences, and GoodFellows have merged to create one of the largest live experiences players in Europe. By pooling their strengths under the 360 Experience Group banner, the merged group will span the full breadth of the live industry and bring together 16 specialized companies, including Live Legends, Unlimited Productions, Unbranded, TIG Sports and Events and Kumpany. The group will provide end-to-end solutions for the realization of large-scale live entertainment, international sports and public events and impactful brand activations. The combined business will generate over US$90 million in revenue and employ more than 230 people.
Learn moreSRT Marine has completed a placing and subscription
SRT Marine Systems plc has announced an equity raise of at least US$22 million at US$1.10 per share representing a 5.75% discount, through a US$19.4 million accelerated bookbuild placing and a US$2 million subscription by Ocean Infinity, alongside a separate retail offer of up to US$1.3 million.
Learn moreIXICO has completed a fundraising
IXICO plc, a specialist in AI-driven neuroimaging analytics, has completed a US$13.5 million gross capital raise. The funds will be used to support the company’s tech bio strategy, which will see IXICO partner its platform to maximize its potential.
Learn more